JAZZJazz Pharmaceuticals plc
Price
+70%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, undemanding price, growth steady, the market undecided.
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $1.21B in Q2 2026 (quarter ended Jun 30, 2026), up 16% from the same quarter a year earlier. That came with net income of $193M (16% of revenue). For the full year FY2025, revenue was $4.27B (+4.9% year on year) and net income −$356M. Its largest product in Q2 2026 was Oncology at $362M, 31% of the disclosed total, ahead of Epilepsy at 25%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 9, 2026On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company” ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.Director or officer change · Form 8-K
- Sep 23, 2026For the purpose of extending the maturity date and repricing the outstanding U.S. dollar term loan B-2 facility incurred on July 19, 2024 (the “Tranche B-2 Dollar Term Loans”), on September 23, 2026, Jazz Financing Lux S.à r.l., a private limited liability company ( société à responsabilité limitée ) incorporated and …Material agreement entered · Form 8-K
- Sep 15, 2026Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $1.15BThe company’s own SEC segment disclosure.
- Oncology$362.3M31%
- Epilepsy$292.1M25%
- Zepzelca$105.8M9%
- Rylaze Enrylaze$99.5M9%
- Defitelio Defibrotide$62.0M5%
- Product And Services Royalties And Contract$52.2M5%
- Other (6)$177.7M15%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.